Table 1. Relative IC 50 (µM) for MCL... | American Society of Hematology

Table 1.

Relative IC₅₀ (µM) for MCL lines treated with the indicated agents for 48 hours

	Mino	JeKo-1	Z-138	Maver-1	Rec-1	Granta519
AUY922	0.012	0.0068	0.0039	0.0038	0.0075	0.006
AT13387	0.13	0.075	0.065	0.33	0.13	0.13
PU-H71	0.38	0.072	0.04	0.073	0.29	0.11
HSP990	0.48	11	0.005	0.011	0.021	0.24
17-AAG	0.51	0.15	0.029	0.14	10	0.67
Ibrutinib	6.8	2.7	12	6.6	6.5	22
ABT737	ND	1.0	0.0046	0.017	0.26	0.12
Bortezomib	ND	0.002	0.002	0.0025	0.0031	0.0013
Bendamustine	ND	160	36	150	490	3000
Idelalisib	ND	6.9	7.7	27	67	19
Cytarabine	ND	0.03	0.016	0.022	0.07	0.14
Doxorubicin	ND	0.098	0.0069	0.057	0.088	0.015
Ifosfamide	ND	1200	400	540	1200	690
Hydrocortisone	ND			550	320	860

	Mino	JeKo-1	Z-138	Maver-1	Rec-1	Granta519
AUY922	0.012	0.0068	0.0039	0.0038	0.0075	0.006
AT13387	0.13	0.075	0.065	0.33	0.13	0.13
PU-H71	0.38	0.072	0.04	0.073	0.29	0.11
HSP990	0.48	11	0.005	0.011	0.021	0.24
17-AAG	0.51	0.15	0.029	0.14	10	0.67
Ibrutinib	6.8	2.7	12	6.6	6.5	22
ABT737	ND	1.0	0.0046	0.017	0.26	0.12
Bortezomib	ND	0.002	0.002	0.0025	0.0031	0.0013
Bendamustine	ND	160	36	150	490	3000
Idelalisib	ND	6.9	7.7	27	67	19
Cytarabine	ND	0.03	0.016	0.022	0.07	0.14
Doxorubicin	ND	0.098	0.0069	0.057	0.088	0.015
Ifosfamide	ND	1200	400	540	1200	690
Hydrocortisone	ND			550	320	860

Data represent the mean of 2 to 3 independent experiments performed in triplicate.

ND, not determined.